Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSTEAD trial in sensitized kidney transplant recipients without pre-existing donor-specific antibodies
2022-502007-30-00Phase 3Authorised
- Sponsor
- CHRU Tours
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in kidney allograft rejection comparing rATG induction with basiliximab induction (2 arms). Primary endpoint: Incidence of biopsy-proven acute rejection at 1 year. Planned start Jun 2023; status: authorised.
02
Drugs
antithymocyte globulin rabbitbasiliximab
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2022-502007-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502007-30-00.